Crohn’s Disease Therapeutics Market Size, Share & Trends Report

Crohn’s Disease Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Anti-inflammatory, Immune System Suppressors, Antibiotics, Surgical), By Region, And Segment Forecasts, 2018 - 2025

  • Published Date: Aug, 2018
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-424-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 100

Industry Insights

The global Crohn’s disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% during the forecast period. Growing prevalence of the disease, along with increase in number of pipeline drugs, is expected to be a key factor driving the market.

U.S. Crohn’s disease therapeutics market

Prevalence of Crohn’s disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year.

Constant efforts in the development of biosimilars is steering industry growth. Low cost of biosimilars is one of its major benefits, which has resulted in cumulative savings within the healthcare system in U.S. and Europe. Reduced cost can result in increased access to biologic therapies, thus improving patient care.

Rising development of novel biological agents and anti-cytokine agents with a different mechanism of action and use of stem cells in treating the disease is anticipated to drive the industry in future. For instance, Infliximab and Adalimumab are some of the TNF-agents that have proved to be efficacious in treating the condition.

In addition, increase in number of pipeline drugs is anticipated to accentuate growth. Currently, there are around 40 drugs in the pipeline and commercialization of five drugs is expected in 2019. For instance, Celgene Corporation’s mongersen (GED-0301) is currently in phase III trial for Crohn’s disease and is expected to be launched in 2019. As of 2016, 27 biosimilars were in the pipeline, with 11 of them in phase III trials.

Therapy Type Insights

Based on therapy type, the market is broadly categorized into surgical and non-surgical, with the latter comprising anti-inflammatory, immune system suppressors, antibiotics, and others. The anti-inflammatory segment dominated the overall Crohn’s disease therapeutics market in terms of revenue in 2016. Anti-inflammatories are first line therapy drugs and are more targeted and effective.

The immune system suppressors segment is slated to clock a CAGR of 3.2% during the forecast period. Immune system suppressors have shown promising safety and efficacy. Reduced rate of mortality, hospitalization, and surgery, coupled with improved patient quality of life, is expected to drive the segment.

Global Crohn’s disease therapeutics market

Companies such as Genentech Inc. and Celgene Corporation are currently focusing on developing immune system suppressors for the treatment of this condition. For instance, etrolizumab of Genentech Inc., an immune system suppressor, is under clinical investigation. This drug has shown promising safety and efficacy in phase II clinical studies. Approval of these products may support the growth of this segment in future.

Regional Insights

North America dominated the global market in terms of revenue in 2016. Established R&D infrastructure, development of novel therapeutics, and rising prevalence of the disease are key factors contributing to its growth.

According to the Crohn’s & Colitis Foundation, 1.6 million Americans suffer from the condition. High prevalence of the condition, along with strong healthcare infrastructure, has triggered the introduction of initiatives for novel treatment methods and making them accessible to patients. Europe was the second-largest revenue generating region in 2016. Highly established healthcare infrastructure, coupled with rise in disease prevalence and increase in R&D initiatives, is expected to drive the regional market.

The Asia Pacific market is poised to exhibit a CAGR of 4.2% over the forecast period. Japan and China are considered to be the most promising markets in the region. Change in dietary habits augments market growth.

Crohn’s Disease Therapeutics Market Share Insights

The global market is marked by extensive strategic collaboration as a result of its consolidated nature. Some of the major players are Johnson & Johnson Services Inc.; Pfizer Inc.; Allergan; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Celgene Corporation; Perrigo Company PLC; Ferring B.V.; Salix Pharmaceuticals; Gilead Sciences Inc.; Genentech Inc.; and UCB India Private Limited.

Collaborations with research institutes and acquisitions of small players are key strategies undertaken by players to attain a stable position in the market. Focus is also on development of novel products for treatment. For instance, in 2016, Johnson & Johnson announced the approval of Stelara by the FDA for the treatment of Crohn’s disease.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                  

Revenue in USD Billion and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa

Report coverage              

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global Crohn’s disease therapeutics market report on the basis of therapy type and region:

  • Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Non-Surgical

      • Anti-Inflammatory

      • Immune system suppressors

      • Antibiotics

      • Others

    • Surgical

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • Japan

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
BI Library Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified